Cargando…
Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308961/ https://www.ncbi.nlm.nih.gov/pubmed/34371763 http://dx.doi.org/10.3390/pharmaceutics13071072 |
_version_ | 1783728408972230656 |
---|---|
author | Aido, Ahmed Zaitseva, Olena Wajant, Harald Buzgo, Matej Simaite, Aiva |
author_facet | Aido, Ahmed Zaitseva, Olena Wajant, Harald Buzgo, Matej Simaite, Aiva |
author_sort | Aido, Ahmed |
collection | PubMed |
description | Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the “activating” effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications. |
format | Online Article Text |
id | pubmed-8308961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83089612021-07-25 Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) Aido, Ahmed Zaitseva, Olena Wajant, Harald Buzgo, Matej Simaite, Aiva Pharmaceutics Article Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the “activating” effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications. MDPI 2021-07-13 /pmc/articles/PMC8308961/ /pubmed/34371763 http://dx.doi.org/10.3390/pharmaceutics13071072 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Aido, Ahmed Zaitseva, Olena Wajant, Harald Buzgo, Matej Simaite, Aiva Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) |
title | Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) |
title_full | Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) |
title_fullStr | Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) |
title_full_unstemmed | Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) |
title_short | Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) |
title_sort | anti-fn14 antibody-conjugated nanoparticles display membrane tweak-like agonism (†) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308961/ https://www.ncbi.nlm.nih.gov/pubmed/34371763 http://dx.doi.org/10.3390/pharmaceutics13071072 |
work_keys_str_mv | AT aidoahmed antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism AT zaitsevaolena antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism AT wajantharald antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism AT buzgomatej antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism AT simaiteaiva antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism |